US FDA approves Revolution Medicines' pancreatic cancer drug
The once-daily pill cut death risk by 60% in a 500-patient trial and is the first approved drug to target KRAS-driven pancreatic cancer.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
296 Articles
296 Articles
FDA approves pancreatic cancer drug that’s shown to improve survival
WASHINGTON, D.C. — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of cancer.FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, which blocks a mutated protein that fuels tumor growth in more than 90 percent of pancreatic cancer cases. It’s an approach that previou…
FDA Nod for Daraxonrasib Marks First RAS-Targeted Advance in Metastatic Pancreatic Cancer
Pancreatic cancer has long carried one of the bleakest outlooks in oncology. Most patients receive a diagnosis after the disease has spread. Standard chemotherapy offers limited gains. Survival often measures in months. Yet on August 26, 2026, the FDA approved Rasonque (daraxonrasib), an oral once-daily RAS inhibitor from Revolution Medicines. The decision arrived 6.5 months ahead of schedule. It delivers the first approved therapy that directly…
In metastatic pancreatic cancer, Rasonque prolongs survival from 6.7 to 13.2 months. FDA allowed it prematurely.
FDA approves breakthrough drug to treat advanced pancreatic cancer
(ABC) — The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque from Revolution Medicines. The daily pill targets multiple forms of a protein called RAS, which is a main driver of tumor growth. A late-stage clinical trial with 500 patients showed that the median overall survival nearly d…
FDA Approves Pill That Nearly Doubled Median Survival In Pancreatic Cancer Trial
FDA Approves Rasonque For Pancreatic Cancer Image by CanvaThe U.S. Food and Drug Administration approved a first-in-class pill Wednesday for certain patients with metastatic pancreatic cancer after a Phase III trial found that the treatment nearly doubled median survival compared with standard chemotherapy. Rasonque, known generically as daraxonrasib, is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
